Arya Roy, Hematology-Oncology Fellow at Roswell Park Comprehensive Cancer Center, shared a post on X:
“Exciting results from EMBER-3 study!
Imlunestrant and abemaciclib improved PFS in all-comers and patients with ESR1 mutation.
Great 2L option for HR+ HER2 neg BC patients.
Approval: all patients vs patients with ESR1 mutation?”
Arya Mariam Roy is a Hematology-Oncology Fellow at Roswell Park Comprehensive Cancer Center and an Assistant Professor of Breast Medical Oncology at Ohio State University. Arya is a doctor of Internal Medicine who completed her residency at the University of Arkansas for Medical Sciences, Little Rock. She is interested in solid tumors with a focus on clinical research in breast cancer, genitourinary malignancies, and neuroendocrine tumors.
